## LRCX: Lam Research Corporation - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.6% in lower entry zone (4.0-10.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (3.2%) confirms momentum alignment. Strong momentum (+6.5% 5-day acceleration). Outperforming sector by 5.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($155.56)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Micron vs. Lam Research: Which Stock Has Better Upside Potential?**
- Source: Yahoo! Finance Canada | 20251208T130842 | Somewhat-Bullish | Relevance: 99%
-  Micron Technology (MU) and Lam Research (LRCX) are both benefiting from the semiconductor boom and AI demand, but Micron appears to be the better investment due to its stronger near-term growth profile and lower valuation. Micron's focus on memory chips and HBM for AI, coupled with its diversification strategy, has led to significant revenue and EPS growth. Although Lam Research provides essential tools for chip manufacturing and also benefits from AI trends, Micron's P/E multiple is lower despite higher projected earnings growth, making it a "Strong Buy" according to Zacks.

**2. Morgan Stanley Hikes Lam Research (LRCX) PT to $158, Keeps Equal Weight on Increased 2027 Wafer Fab Equipment Forecast**
- Source: Insider Monkey | 20251208T060836 | Somewhat-Bullish | Relevance: 99%
-  Morgan Stanley analyst Shane Brett increased the price target for Lam Research (LRCX) to $158 while maintaining an Equal Weight rating, citing an increased 2027 Wafer Fab Equipment (WFE) forecast. The company reported strong Q1 2026 revenues of $5.32 billion and provided optimistic guidance for Q2 2026, projecting ~$5.2 billion revenues. Despite the positive outlook, the article suggests that other AI stocks might offer greater return potential.

**3. Lam Research stock hits all-time high at 167.29 USD By Investing.com**
- Source: Investing.com India | 20251210T191233 | Bullish | Relevance: 99%
- Lam Research stock reached an all-time high of $167.29, reflecting a 123.4% increase over the past year and strong investor confidence. The company demonstrates robust fundamentals with a P/E ratio of 36.36 and 25.66% revenue growth, maintaining a "GREAT" financial health score. Analysts have raised price targets, citing strong demand and growth opportunities in the wafer fabrication equipment sector.

**4. Lam Research Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251209T163400 | Bullish | Relevance: 99%
- Shares of Lam Research Corp. (LRCX) rose 1.89% to $165.81 on Tuesday, outperforming the broader market which saw declines for both the S&P 500 Index and the Dow Jones Industrial Average. This marks the third consecutive day of gains for the stock.

**5. SVB Wealth LLC Acquires Shares of 28,255 Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251209T124742 | Somewhat-Bullish | Relevance: 98%
-  SVB Wealth LLC has acquired 28,255 shares of Lam Research Corporation, valued at approximately $2.75 million, establishing a new position in the semiconductor company. This comes as other institutional investors have also adjusted their holdings, with institutional ownership now standing at around 84.61%. Despite recent insider selling, Lam Research reported a strong quarterly performance, exceeding EPS and revenue expectations, and analysts currently rate the stock as a "Moderate Buy" with an average target price of $152.87.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $158 | $137 | +15% |
| 2025-11-25 | UBS | $175 | $165 | +6% |
| 2025-11-12 | Citigroup | $190 | $175 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 6 ($14.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+0.3%)
- Blackrock Inc.: 9.9% (+1.7%)
- JPMORGAN CHASE & CO: 4.8% (+47.4%)
- State Street Corpora: 4.8% (+0.4%)
- Geode Capital Manage: 2.7% (-0.5%)

### Key Risks

1. Heavy insider selling: $14M sold (6 transactions in 90 days).
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Momentum building: MRS_20 improving +6.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.39 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 62%, ROA 20%, margin 30%). Balance sheet: strong liquidity (2.2x), $1.6B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($14.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $212.2B |
| Beta | 1.78 |
| 52W Range | $56.32 - $169.69 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.39 |
| Forward P/E | 30.1 |
| Current P/E | 34.9 |
| YoY Growth | 15.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.1% to 6.6% (+6.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 at 3.2% confirms short-term momentum alignment. AM_20 at 9.2% shows strong absolute momentum above own 20MA. Outperforming sector by 5.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.28), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.60% (CS: 86) | Strong |
| RSI_14 | 64.6 | Neutral |
| MACD Histogram | 1.28 | Bullish |
| vs SMA20 | 1.091x | Above |
| vs SMA50 | 1.110x | Above |
| vs SMA200 | 1.594x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $168.26
- **Stop Loss:** $155.56 (7.5% risk)
- **Target:** $187.31 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 94
- **Position Value:** $15,816.44
- **Portfolio %:** 15.82%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-28 (Est: $1.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.22 | $1.26 | +3.3% |
| 2025Q2 | $1.21 | $1.33 | +10.4% |
| 2025Q1 | $1.00 | $1.04 | +4.1% |
| 2024Q4 | $0.88 | $0.91 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*